CClinicalTrials.gg
CompletedNCT06009614Updated May 20, 2024

Radicle GI Health: A Study of Health and Wellness Products on GI Health and Other Health Outcomes

An interventional study of Radicle GI Health Placebo Control Form 1 and Radicle GI Health Active Study Product 1.1 Usage in Digestion, Abdominal Pain and GI Disorders, sponsored by Radicle Science. Completed at 1 site in United States. Open to participants aged 21 Years to 105 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-20.

Sponsored by Radicle Science · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
2,180
Allocation
Randomized
Ages
21 Years to 105 Years
Sex
All
01

Study summary

A randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on gastrointestinal (GI) health and other health outcomes

Read the detailed description

This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for less bloating or indigestion, (2) indicate an interest in taking a health and wellness product to potentially help their bloating or indigestion, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

02

Conditions studied

  • Digestion
  • Abdominal Pain
  • GI Disorders

Browse trials for

03

In context

Abdominal Pain

338 studies on the registry are indexed under Abdominal Pain; 55 are open to participants now.

This study's enrollment of 2,180 is above the median of 72 across 250 interventional studies indexed under Abdominal Pain.

Browse Abdominal Pain studies →

Lead sponsor

Radicle Science is the lead sponsor of 64 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
  • Resides in the United States
  • Endorses less bloating or indigestion as a primary desire
  • Has the opportunity for at least 20% improvement in their primary health outcome score
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion criteria

Exclusion Criteria:

  • Reports being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • The calculated validated health survey (PRO) score during enrollment represents less than mild severity
  • Reports a diagnosis of liver or kidney disease
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Reports current enrollment in another clinical trial
  • Lack of reliable daily access to the internet
  • Reports current or recent (within 3 months) use of chemotherapy or immunotherapy
  • Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied, or a substantial safety risk: Anticoagulants, antihypertensives, anti-anxiolytics, antidepressants, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs (monoamine oxidase inhibitors), or thyroid products
  • Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: NYHAA (New York Heart Association) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,180 participants (actual)

Study arms

  • Placebo comparator
    Placebo Control 1

    GI Health Product Form 1 - control

    Dietary Supplement: Radicle GI Health Placebo Control Form 1

  • Experimental
    Active Product 1.1

    GI Health Product Form 1 - active product 1

    Dietary Supplement: Radicle GI Health Active Study Product 1.1 Usage

  • Placebo comparator
    Placebo Control 2

    GI Health Product Form 2 - control

    Dietary Supplement: Radicle GI Health Placebo Control Form 2

  • Experimental
    Active Product 2.1

    GI Health Product Form 2 - active product 1

    Dietary Supplement: Radicle GI Health Active Study Product 2.1 Usage

  • Experimental
    Active Product 2.2

    GI Health Product Form 2 - active product 2

    Dietary Supplement: Radicle GI Health Active Study Product 2.2 Usage

  • Placebo comparator
    Placebo Control 3

    GI Health Product Form 3 - control

    Dietary Supplement: Radicle GI Health Placebo Control Form 3

  • Experimental
    Active Product 3.1

    GI Health Product Form 3 - active product 1

    Dietary Supplement: Radicle GI Health Active Study Product 3.1 Usage

Interventions

  • Dietary supplementRadicle GI Health Placebo Control Form 1

    Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

  • Dietary supplementRadicle GI Health Active Study Product 1.1 Usage

    Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.

  • Dietary supplementRadicle GI Health Placebo Control Form 2

    Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.

  • Dietary supplementRadicle GI Health Active Study Product 2.1 Usage

    Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.

  • Dietary supplementRadicle GI Health Active Study Product 2.2 Usage

    Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.

  • Dietary supplementRadicle GI Health Placebo Control Form 3

    Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.

  • Dietary supplementRadicle GI Health Active Study Product 3.1 Usage

    Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change in GI (Gastrointestinal) - related Quality of Life (QOL)

    Mean difference in GI-related QOL as assessed by Digestion-associated QOL Questionnaire (DGLQ) (scale 0%-100%; with higher scores corresponding to worse GI-related QOL)

    Time frame: 6 weeks

Secondary outcomes

  1. Change in abdominal pain

    Mean difference in abdominal pain as assessed by Patient Reported Outcome Measurement System (PROMIS) Belly Pain 5A (scale 2-25; with higher scores corresponding to more severe abdominal pain)

    Time frame: 6 weeks

  2. Change in gas/bloating

    Mean Difference in Gas/Bloating as assessed by PROMIS GI Gas and Bloating 13A (scale 2-60; with higher scores corresponding to more severe gas/bloating)

    Time frame: 6 weeks

  3. Change in feelings of anxiety

    Mean difference in anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)

    Time frame: 6 weeks

  4. Minimal clinically important difference (MCID) in GI-related QOL

    Likelihood of experiencing MCID in GI-related QOL as assessed by Digestion-associated QOL Questionnaire (DGLQ)

    Time frame: 6 weeks

  5. Minimal clinically important difference (MCID) in abdominal pain

    Likelihood of experiencing MCID in abdominal pain as assessed by PROMIS Belly Pain 5A

    Time frame: 6 weeks

  6. Minimal clinically important difference (MCID) in gas/bloating

    Likelihood of experiencing MCID in gas/bloating PROMIS GI Gas and Bloating 13A

    Time frame: 6 weeks

Other outcomes

  1. Change in mood (emotional distress-depression)

    Mean difference in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)

    Time frame: 6 weeks

  2. Change in libido

    Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 2-10; with higher scores corresponding to greater interest in sexual activity)

    Time frame: 6 weeks

07

Study locations

1 site
  • Radicle Science, Inc
    Del Mar, California 92014, United States
08

References and documents

Individual participant data

Plan to share: No — Data will not be shared with researchers outside of Radicle Collaborators on this study.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06009614
Lead sponsor
Radicle Science
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Aug 15, 2023
Primary completion
Nov 30, 2023
Completion
Feb 20, 2024
Last update
May 20, 2024

Study contacts

Emily K. Pauli, PharmD
principal investigator · Radicle Science, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion